Efficacy of Different Clones of p16 in Comparison to HPV DNA PCR in Head and Neck Cancer: A Review

Background: Human papillomavirus (HPV), particularly HPV type 16, is becoming more prevalent as a cause of squamous cell carcinomas of the head and neck, particularly in the oropharyngeal region. HPV-positive cancers are distinguished from HPV-negative cancers by their molecular mechanisms, response to treatment, and prognosis. Epigenetic alterations, such as dysregulation of miRNAs, play an important role in the development of oral cancers and may also be useful for diagnostic purposes. The protein p16 is an established biomarker of HPV infection, the prognostic role of RB1-associated p16 overexpression remains unclear. Aim: How does the efficacy of different p16 antibody clones compare to HPV DNA PCR testing in detecting HPV-associated head and neck cancers. Result: The use of p16 immunohistochemistry (IHC) as a surrogate marker for HPV-related head and neck squamous cell carcinoma (HNSCC) is effective, although the accuracy of p16 IHC alone can be influenced by factors such as the specific clone of antibody used for immunostaining, tumor location, and the use of additional tests. The E6H4 clone was shown to have the highest reliability with sensitivities between 89.2% and specificities as high as 77.4%, while the performance of other clones was much more variable. Overall, when p16 IHC is used in combination with HPV DNA/RNA based assay testing, there is significantly improved specificity and prognostic accuracy; therefore, the use of an integrated multimodal approach for diagnosis rather than using p16 expression alone is recommended. Conclusion: p16 IHC, especially with the E6H4 clone, is a useful surrogate marker for HPV-driven OPSCC, but its reliability decreases in non-oropharyngeal sites. Combining p16 with HPV-specific tests remains the most accurate strategy and should guide future standardized diagnostic approaches.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-14
DOI
https://doi.org/10.25258/ijddt.16.81s.106
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of Different Clones of p16 in Comparison to HPV DNA PCR in Head and Neck Cancer: A Review

Sima Chauhan, Yogesh Kumar Singh, Aarti Mittal, Anupama Sharma et al.
International Journal of Drug Delivery Technology
Head and Neck Cancer Studies
article

Efficacy of Different Clones of p16 in Comparison to HPV DNA PCR in Head and Neck Cancer: A Review

Sima Chauhan, Yogesh Kumar Singh, Aarti Mittal, Anupama Sharma, Sourav Debnath, Prajwal Anil Gupta
article en

Abstract

Background: Human papillomavirus (HPV), particularly HPV type 16, is becoming more prevalent as a cause of squamous cell carcinomas of the head and neck, particularly in the oropharyngeal region. HPV-positive cancers are distinguished from HPV-negative cancers by their molecular mechanisms, response to treatment, and prognosis. Epigenetic alterations, such as dysregulation of miRNAs, play an important role in the development of oral cancers and may also be useful for diagnostic purposes. The protein p16 is an established biomarker of HPV infection, the prognostic role of RB1-associated p16 overexpression remains unclear. Aim: How does the efficacy of different p16 antibody clones compare to HPV DNA PCR testing in detecting HPV-associated head and neck cancers. Result: The use of p16 immunohistochemistry (IHC) as a surrogate marker for HPV-related head and neck squamous cell carcinoma (HNSCC) is effective, although the accuracy of p16 IHC alone can be influenced by factors such as the specific clone of antibody used for immunostaining, tumor location, and the use of additional tests. The E6H4 clone was shown to have the highest reliability with sensitivities between 89.2% and specificities as high as 77.4%, while the performance of other clones was much more variable. Overall, when p16 IHC is used in combination with HPV DNA/RNA based assay testing, there is significantly improved specificity and prognostic accuracy; therefore, the use of an integrated multimodal approach for diagnosis rather than using p16 expression alone is recommended. Conclusion: p16 IHC, especially with the E6H4 clone, is a useful surrogate marker for HPV-driven OPSCC, but its reliability decreases in non-oropharyngeal sites. Combining p16 with HPV-specific tests remains the most accurate strategy and should guide future standardized diagnostic approaches.

International Journal of Drug Delivery TechnologyVol. 16(81s)
NIMS University (IN)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon